Gold prices edged higher; remain near $3,400/oz as Sept rate cut bets rise
Evotec SE (NASDAQ:EVO) announced Wednesday that it is planning, together with Sandoz (SIX:SDZ) AG, a potential sale of the Just – Evotec Biologics site located in Toulouse, France. The information was disclosed in a press release statement included in the company’s latest filing with the U.S. Securities and Exchange Commission.
According to the filing, Evotec and Sandoz are considering the transaction as part of an evolution of their strategic partnership. The Toulouse site, operated under the Just – Evotec Biologics brand, is a facility focused on biologics development and manufacturing.
Details regarding the potential sale, including financial terms, timeline, and possible buyers, were not provided in the filing. The announcement states only that both companies are currently planning the transaction and have agreed on the potential sale.
Evotec SE is headquartered in Hamburg, Germany and is listed on the NASDAQ exchange under the ticker EVO. Sandoz AG is a global pharmaceutical company specializing in generic and biosimilar medicines.
The information is based on a press release statement contained in Evotec’s Form 6-K filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.